Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus

Human Gene Therapy

Volumn 8, Issue 10, 1997, Pages 1231-1241

  Martineau, Darlene ^a   Klump, Wolfgang M ^a   McCormack, James E ^a   DePolo, Nicholas J ^a   Kamantigue, Edgar ^a   Petrowski, Mary ^a   Hanlon, James ^a   Jolly, Douglas J ^a   Mento, Steven J ^a   Sajjadi, Nancy ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; CLINICAL TRIAL; CLONING VECTOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD AND DRUG ADMINISTRATION; GENE TARGETING; GENE THERAPY; GENETIC RECOMBINATION; HUMAN; HUMAN CELL; MURINE LEUKEMIA VIRUS; NONHUMAN; POLYMERASE CHAIN REACTION; RETROVIRUS INFECTION; SCREENING; VIRUS DNA CELL DNA INTERACTION; VIRUS PARTICLE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE; MURINE LEUKEMIA VIRUS; UNIDENTIFIED RETROVIRUS;

EID: 16944365709     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.10-1231     Document Type: Article

References (29)

1. ABRAHAM, G.N., and KHAN, A.S. (1990). Human endogenous retroviruses and immune disease. Clin. Immunol. Immunopath. 56, 1-8.
2. AHMED, F., STEINHOFF, M.C., RODRIGUEZ-BARRADAS, M.C., HAMILTON, R.G., MUSHER, D.M., and NELSON, K.E. (1996). Effect of human immunodeficiency virus type 1 infection on the antibody response to glycoprotein conjugate pneumococial vaccine: results from a randomized trial. J. Infect. Dis. 173, 83-90.
3. BODINE, D.M., MCDONAGH, K.T., BRANDT, S.J., NEY, P.A., AGRICOLA, B., BYRNE, E., and NIENHUIS, A.W. (1990). Development of high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 87, 3738-3742.
4. CHADA, S., DeJESUS, C., TOWNSEND, K., LEE, W.T.L., LAUBE, L., JOLLY, D., CHANG, S.M., and WARNER, J.F. (1993). Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 III B env-specific cytotoxic T lymphocyte. J. Virol. 67, 3409-3417.
5. CHARGELEGUE, O.D., COLVIN, B.T., and O'TOOLE, C.M. (1993). A 7-year analysis of anti-gag (p17 and p24) antibodies in HIV-1-seropositive patients with hemophilia: immunoglobulin G titre and avidity are early predictors of clinical course. AIDS 7 (Suppl. 2), 587-590.
6. CHONG, H., and VILE, R. (1996). Replication-competent retrovirus produced by a 'split-function' third generation amphotropic packaging cell line. Gene. Ther. 3, 624-629.
7. CORNETTA, K., MOEN, R.C., CULVER, K., MORGAN, R.A., MCLACHLIN, J.R., STURM, S., SELEGUE, J., LONDON, W., BLAESE, R.M., and ANDERSON, F.W. (1990). Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1, 15-30.
8. CORNETTA, K., MORGAN, R.A., GILLIO, A., STURM, S., BALTRUCKI, L., O'REILLY, R., and ANDERSON, W.F. (1991). No retroviremia or pathology in long-term follow-up of monkeys exposed to a marine amphotropic retrovirus. Hum. Gene Ther. 2, 215-219.
9. DONAHUE, R.E., KESSLER, S.W., BODINE, D., MCDONAGH, K., BYRNE E., RAFFIELD, M., MOEN, R., BACHER, J., ZSEBO, K.M., and NIENHUIS, A.W. (1992). Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J. Exp. Med. 176, 1125-1135.
10. FRANKLIN, G.C., CHRETIEN, S., HANSON, I.M., ROCHEFORT, H., MAY, F.E.B., and WESTLEY, B.R. (1988). Expression of human sequences related to that of mouse mammary tumor virus. J. Virol. 62, 1203-1210.
11. HERSH, E.M., HANNA, M.G., GUTTERMAN, J.C., MAVLIGIT, G., YURCONIC, M., and GSCHWIND, C.R. (1974). Human immune response to active immunization with Rauscher leukemia virus humoral immunity. J. Natl. Cancer Inst. 53, 327-333.
12. IRWIN, M.J., LAUBE, L.S., LEE, V., AUSTIN, M., CHADA, S., ANDERSON, C., TOWNSEND, K., JOLLY, D.J., and WARNER, J.F. (1994). Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J. Virol. 68, 5036-5044.
13. JOLLY, D. (1994). Viral vector systems for gene therapy. Cancer Gene Ther. 1, 51-64.
14. + lymphocytes. AIDS 8, 469-476.
15. + T lymphocytes in adults infected with human immunodeficiency virus. Clin. Infect. Dis. 10, 1197-1203.
16. LOWER, R., LOWER, J., and KURTH, R. (1996). The virus in all of us: characteristics and biological significance of the human endogenous retrovirus sequences. Proc. Natl. Acad. Sci. USA 93, 5177-5184.
17. MCCORMACK, J.E., MARTINEAU, D., DEPOLO, N., MAIFERT, S., AKBARIAN, L., TOWNSEND, K., LEE, W., IRWIN, M., SAJJADI, N., JOLLY, D.J., and WARNER, J. (1997). Anti-vector immunoglobulin induced by retroviral vectors. Hum. Gene Ther. 8, 1263-1273.
18. MILLER, A.D., MILLER, D.G., GARCIA, J.V., and LYNCH, C.M. (1993). Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217, 581-599.
19. MILLER, A.D., LAW, M.F., and VERMA, I.M. (1985). Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol. Cell. Biol. 5, 431-437.
20. ONO, M., KAWAKAMI, M., and USHIKUBO, H. (1987). Stimulation of expression of human endogenous retrovirus genome by female steroid hormones in human breast cancer. J. Virol. 61, 2059-2062.
21. OTTO, E., JONES-TROWER, A., VANIN, E.F., STAMBAUGH, K., MUELLER, S.N., ANDERSON, W.F., and MCGARRITY, G.J. (1994). Characterization of a replication-competent retrovirus resulting from recombination of packaging and vector sequences. Hum. Gen. Ther. 5, 567-575.
22. PRUSSAK, C., and HERMANN, S. (1995). Methods for preserving recombinant viruses. Patent Application PCT WO 95/10601.
23. QUERY, C.C., and KEENE, J.D. (1987). A Human autoimmune protein associated with U1 RNA contains a region of homology that is cross-reactive with retroviral p30gag antigen. Cell 51, 211-220.
24. REPASKE, R., STEELE, P.E., O'NEILL, R.R., RABSON, A.B., and MARTIN, M.A. (1985). Nucleotide sequence of a full-length human endogenous retroviral segment. J. Virol. 54, 764-772.
25. RUCHETON, M., GRAAFLAND, H., FANTON, H., URSULE. L., FERRIER, P., and LARSEN, C.J. (1985). Presence of circulating antibodies against gag-gene MuLV proteins in patients with autoimmune connective tissue disorders. Virology 144, 468-480.
26. SHERMAN, K.E., O'BRIEN, J., GUTIERREZ, A.G., HARRISON, S., URDEA, M., NEUWALD, P., and WILBER, J. (1993). Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J. Clin. Microbiol. 31, 2679-2682.
27. URDEA, S.M. (1994). Branched DNA Signal Amplification. Does bDNA represent post-PCR amplification technology? Bio/Technology 12, 926-928.
28. US Food and Drug Administration, Center of Biologies Evaluation and Research, Vaccines and Related Biological Products Advisory Committee, transcript of meeting, 25 October 1993. Draft points to consider in gene therapy, 1996. Available from the Center for Biologies, FDA, Bethesda, MD 20205, USA.
29. VANIN, E.F., KALOSS, M., BROSCIUS, C., and NIENHUIS, A.W. (1994). Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J. Virol. 68, 4241-4250.